To date, several LSD1 inhibitors are already in various phases of clinical trials (tranylcypromine, ORY-1001, ORY-2001, GSK-2879552, INCB059872, IMG-7289, TAK418, CC-90011 and SP2577), especially for the treatment of acute myeloid leukemia and small lung cancer cells [107,108]. This evidence concerns the gene KDM1A and acute myeloid leukemia.